



similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. They are metabolized primarily in the liver and then excreted in the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

## **INDICATIONS AND USAGE**

Flurandrenolide Cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

## **CONTRAINDICATIONS**

Topical corticosteroids are contraindicated in patients with a history of hypersensitivity to any of the components of these preparations.

## **PRECAUTIONS**

### **General**

Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.

Conditions that augment systemic absorption include application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.

Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression using urinary-free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, so that supplemental systemic corticosteroids are required.

Pediatric patients may absorb proportionately larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see Pediatric Use under PRECAUTIONS).

If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

In the presence of dermatologic infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, Flurandrenolide cream should be discontinued until the infection has been adequately controlled.

### **Information for the Patient**

Patients using topical corticosteroids should receive the following information and instructions:

1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
2. Patients should be advised not to use this medication for any disorder other than that for which it was prescribed.
3. The treated skin area should not be bandaged or otherwise covered or wrapped in order to be occlusive unless the patient is directed to do so by the physician.
4. Patients should report any signs of local adverse reactions, especially under occlusive dressing.
5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a patient being treated in the diaper area, because these garments may constitute occlusive dressings.
6. Do not use Flurandrenolide cream on the face, underarms, or groin areas unless directed by your

physician.

7. If no improvement is seen within 2 weeks, contact your physician.
8. Do not use other corticosteroid-containing products while using Flurandrenolide cream without first consulting your physician.

### **Laboratory Tests**

The following tests may be helpful in evaluating the HPA axis suppression:

Urinary-free cortisol test

ACTH stimulation test

### **Carcinogenesis, Mutagenesis, and Impairment of Fertility**

Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.

Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.

### **Usage in Pregnancy**

Pregnancy Category C

Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively for pregnant patients or in large amounts or for prolonged periods of time.

### **Nursing Mothers**

It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities *not* likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

### **Pediatric Use**

Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than do mature patients because of a larger skin surface area to body weight ratio.

Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of pediatric patients.

### **ADVERSE REACTIONS**

The following local adverse reactions are reported infrequently with topical corticosteroids but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence:

Burning  
Itching  
Irritation  
Dryness  
Folliculitis  
Hypertrichosis  
Acneform eruptions  
Hypopigmentation  
Perioral dermatitis  
Allergic contact dermatitis

The following may occur more frequently with occlusive dressings:

Maceration of the skin  
Secondary infection  
Skin atrophy  
Striae  
Miliaria

### **Postmarketing Adverse Reactions**

The following adverse reactions have been identified during post approval use of flurandrenolide, USP. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

*Skin:* skin striae, hypersensitivity, skin atrophy, contact dermatitis and skin discoloration.

### **OVERDOSAGE**

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see **PRECAUTIONS**).

### **DOSAGE AND ADMINISTRATION**

For moist lesions, a small quantity of the cream should be rubbed gently into the affected areas 2 or 3 times a day.

Therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary.

Flurandrenolide cream should not be used with occlusive dressings unless directed by a physician. Tight-fitting diapers or plastic pants may constitute occlusive dressings.

### **HOW SUPPLIED**

Flurandrenolide Cream, USP is supplied in aluminum tubes as follows:

Flurandrenolide Cream, USP 0.05%:

120 g (NDC 51672-5301-4)

**Keep out of reach of children.**

### **Storage**

Keep tightly closed.

Protect from light.

Store at 20° to 25°C (68° to 77°F) with excursions permitted to 15° to 30°C (59° to 86°F) [See USP controlled room temperature].

**Rx Only**

Mfd. by: DPT Laboratories, San Antonio, TX 78215

Dist. by: **Taro Pharmaceuticals U.S.A., Inc.**, Hawthorne, NY 10532

TARO is a registered trademark of Taro Pharmaceuticals U.S.A., Inc.

Revision: December, 2015

140659-1

**PRINCIPAL DISPLAY PANEL - 120 g Tube Carton**

**NDC 51672-5301-4**

**120 g**

**Flurandrenolide Cream, USP 0.05%**

**FOR EXTERNAL USE ONLY**

**NOT FOR USE IN THE EYES**

**Rx only**



**FLURANDRENOLIDE**

flurandrenolide cream

**Product Information**

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:51672-5301
<b>Route of Administration</b>	TOPICAL		

**Active Ingredient/Active Moiety**

Ingredient Name	Basis of Strength	Strength
Flurandrenolide (UNII: 8EUL29XUQT) (Flurandrenolide - UNII:8EUL29XUQT)	Flurandrenolide	0.5 mg in 1 g

**Inactive Ingredients**

Ingredient Name	Strength
Cetyl Alcohol (UNII: 936JST6JCN)	
Citric Acid Monohydrate (UNII: 2968PHW8QP)	
Mineral oil (UNII: T5L8T28FGP)	
Polyoxyl 40 stearate (UNII: 13A4J4NH9I)	
Propylene Glycol (UNII: 6DC9Q167V3)	
Sodium Citrate, Unspecified Form (UNII: 1Q73Q2JULR)	
Stearic acid (UNII: 4ELV7Z65AP)	
Water (UNII: 059QF0K00R)	

**Product Characteristics**

Color	WHITE (white to off-white)	Score	
Shape		Size	
Flavor		Imprint Code	
Contains			

**Packaging**

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:51672-5301-4	1 in 1 CARTON	04/25/2016	
1		120 g in 1 TUBE; Type 0: Not a Combination Product		

**Marketing Information**

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA012806	04/25/2016	

**Labeler** - Taro Pharmaceuticals U.S.A., Inc. (145186370)**Establishment**

Name	Address	ID/FEI	Business Operations
DPT Laboratories, Ltd.		832224526	MANUFACTURE(51672-5301)